Comparison of the pulmonary, hepatic and renal extraction of PGI2 and 6-KETO-PGE1

https://doi.org/10.1016/0014-2999(82)90010-3Get rights and content

Abstract

Prostaglandin (PG)I2 and 6-keto-PGE1 were infused into the aortic, arch, femoral vein, renal artery and portal vein in anestized dogs over a dose range to produce aa stable decrease in systemic blood pressure after 7 min of infusion. Mesenteric artery blood flow was measured continously with a non-cannulating electromagnetic flow probe. Parallel log dose-response relationships were seen for decreases in blood pressure and increases in mesenteric blood flow with both prostaglandins when infused into the aortic arch. The dose responses for intra-aortic and intra-aortic and intravenous infusion of PGI2 were not different shifted to the right with intrarenal and intraportal infusions. With 6-keto-PGE1 the dose responses after intravenous, intrarenal and intraportal infusions were all shifted to the right. By comparing doses which reduced blood pressure by 10 mm Hg, the extraction of the PGs by the lungs, kidney and liver was calculated. PGI2 had no significant pulmonary extraction, 31% renal and 75% hepatic extraction. In contrast, 6-keto-PGE1 had extractions of 40, 66 and 51% for pulmonary, renal, and hepatic vascular beds, respectively. We conclude that 6-keto-PGE1 is reasonably well extracted by the lungs, kidney, and liver.

References (12)

There are more references available in the full text version of this article.

Cited by (18)

  • Recent advances in studies of SLCO2A1 as a key regulator of the delivery of prostaglandins to their sites of action

    2021, Pharmacology and Therapeutics
    Citation Excerpt :

    Since then, evidence has accumulated that uptake of PGs such PGE1, PGE2, PGD2, and PGF2α by the lungs is non-linear (Linehan & Dawson, 1979; Piper, Vane, & Wylllie, 1970; Robinson & Hoult, 1982), dependent upon plasma protein binding (C. A. Dawson, Linehan, Rickaby, & Roerig, 1984), and accompanied with rapid metabolism (C. A. Dawson, Cozzini, & Lonigro, 1975). However, metabolites of PGI2 or 6-keto PGF1α were hardly detectable in the lungs (Dusting et al., 1978; Tsunoda, Jackson, Branch, & Gerkens, 1982). Primary metabolites of PGs (15-keto PG and 13,14-dihydro 15-keto PG, Fig. 3B) appeared in the lungs after intravenous infusion, and their appearance was blocked by drugs such as indocyanine green (Pitt, Forder, & Gillis, 1983).

  • Prostaglandin transport

    2002, Prostaglandins and Other Lipid Mediators
  • Biological activities of 6-keto-prostaglandin E<inf>1</inf>

    1984, Prostaglandins, Leukotrienes and Medicine
View all citing articles on Scopus
View full text